National Data Bank for Rheumatic Disease (NDB) Registry Study of Safety in Rheumatoid Arthritis (RA) Patients Treated With Certolizumab Pegol (CZP; Cimzia®) and Non-biologic Disease-modifying Antirheumatic Drug (DMARD) Therapies
Observational
Observational Model: Cohort, Time Perspective: Prospective
Number of participants with lymphoma
Number of participants with lymphoma during the observational period (up to 6 years)
6 years
Yes
Frederick Wolfe, M.D.
Study Director
National Data Bank for Rheumatic Disease
United States: Institutional Review Board
RA0005
NCT01095393
September 2009
February 2016
Name | Location |
---|